Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-7-23
pubmed:abstractText
Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2). It may reduce the risk of cancer formation by affecting the metabolism of arachidonic acid (AA), which has been implicated in the development of cancer. Accordingly, this study was designed to determine the effects of celecoxib on the AA pathway in mouse hepatoma H22 cells. Celecoxib was found to inhibit the proliferation of H22 cells in a dose- and time-dependent manner. Low doses (50 and 100 micromol.L-1) of celecoxib caused an increase in the expression of cytosolic phospholipase A2 (cPLA2), but did not affect the expression of COX-2 in terms of the mRNA and protein levels. Surprisingly, the amount of AA was elevated and the level of prostaglandin E2 (PGE2) was unaltered in the culture supernatant. At higher celecoxib doses (200 and 400 micromol.L-1), the mRNA and protein of both COX-2 and cPLA2 were inhibited. The concentration of AA was increased, and PGE2 level was depressed in H22 cells. The ratio of AA to PGE2 was increased in a dose-dependent manner. Our findings suggest that the imbalance between AA and PGE2, characterized by increased AA at a low dosage and decreased PGE2 at a high dosage of celecoxib, was an important indicator of cytotoxicity of celecoxib on H22 cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1208-6002
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
88
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
603-9
pubmed:meshHeading
pubmed-meshheading:20651831-Animals, pubmed-meshheading:20651831-Arachidonic Acid, pubmed-meshheading:20651831-Biomarkers, Pharmacological, pubmed-meshheading:20651831-Carcinoma, Hepatocellular, pubmed-meshheading:20651831-Cell Line, Tumor, pubmed-meshheading:20651831-Cell Survival, pubmed-meshheading:20651831-Cyclooxygenase 2, pubmed-meshheading:20651831-Cyclooxygenase 2 Inhibitors, pubmed-meshheading:20651831-Dinoprostone, pubmed-meshheading:20651831-Dose-Response Relationship, Drug, pubmed-meshheading:20651831-Down-Regulation, pubmed-meshheading:20651831-Drug Evaluation, Preclinical, pubmed-meshheading:20651831-Liver Neoplasms, pubmed-meshheading:20651831-Metabolic Networks and Pathways, pubmed-meshheading:20651831-Mice, pubmed-meshheading:20651831-Phospholipases A2, pubmed-meshheading:20651831-Pyrazoles, pubmed-meshheading:20651831-Sulfonamides, pubmed-meshheading:20651831-Tumor Markers, Biological
pubmed:year
2010
pubmed:articleTitle
The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway.
pubmed:affiliation
Department of Pharmacology, Norman Bethune College of Medicine, Jilin University, Changchun, Jilin, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't